One-Year Clinical Outcome in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study
Table 1
Baseline demographic, clinical, and echocardiography characteristics of 2020 patients with AF and two subgroups of NVAF and VAF.
Clinical feature
All AF cohort
NVAF (91.5%)
VAF (8.5%)
Age (years),
<0.0001
Women, (%)
1096 (54.3)
981 (53.1)
115 (67.3%)
<0.0001
Hypertension, (%)
1506 (74.6)
1413 (76.2)
93 (54.4)
<0.0001
Type 2 diabetes mellitus, (%)
882 (43.7)
826 (44.7)
56 (32.7)
0.03
Hypercholesterolemia, (%)
280 (13.9)
253 (13.7)
27 (15.8)
0.52
Current cigarette smoking, (%)
909 (45.0)
861 (46.6)
48 (28.1)
<0.0001
BMI (kg/m2),
0.06
Prior or presenting stroke, (%)
224 (11.1)
208 (11.2)
16 (9.4)
0.55
CHD, (%)
215 (10.6)
205 (11.1)
10 (5.8)
0.04
Heart failure, (%)
482 (23.9)
446 (24.1)
36 (21.1)
0.43
CKD, (%)
181 (9.0)
172 (9.3)
9 (5.3)
0.11
Malignancy, (%)
110 (5.4)
96 (5.2)
14 (8.2)
0.14
Nonparoxysmal AF
1292 (64.0)
1158 (62.6)
134 (78.4)
<0.0001
HAS-BLED score,
<0.0001
Enrolled as outpatient setting, (%)
1463 (72.4)
1312 (71.0)
151 (88.3)
<0.0001
LVEF <40%, %
17.8%
18.2%
14.4%
0.26
Left atrial diameter>3.5 cm, %
22.7%
16.1%
96.5%
<0.0001
LVH %
39.0%
39.4%
35.1%
0.34
Pulmonary artery hypertension, %
25.3%
23.5%
45.3%
<0.0001
AF: atrial fibrillation; BMI: body mass index; CHD: coronary heart disease; CKD: chronic kidney disease; LVEF: left ventricular hypertrophy; LVH: left ventricular hypertrophy; NVAF: nonvalvular AF; VAF: valvular AF. Difference between NVAF and VAF patients. Transthoracic echocardiography was done for 90% of patients.
